Anticipating a renaissance, many psychedelic medicine companies have conducted initial public offerings, wherein private companies first issue new shares of stock for sale to the public, making the companies publicly traded entities.1 As of this writing, there are more than 50 publicly traded companies related to the development or administration of psychedeliclike drugs in the US, with at least 3 valued at more than $1 billion. The market for psychedelic substances is projected to grow from $2 billion in 2020 to $10.75 billion by 2027, a growth rate that may even outpace the legal US cannabis market.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Phelps J, Shah RN, Lieberman JA. The Rapid Rise in Investment in Psychedelics—Cart Before the Horse. JAMA Psychiatry. 2022;79(3):189–190. doi:10.1001/jamapsychiatry.2021.3972
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.